No Data
No Data
No Data
No Data
No Data
新銳醫藥:2023年報
Futu NewsApr 24 08:27 ET · Announcements
Xinrui Pharmaceuticals (06108) announced annual results. The net loss attributable to shareholders was about HK$22.2 million, a year-on-year narrowing of about 71.5%
According to the Zhitong Finance App, Xinrui Pharmaceutical (06108) announced results for the year ended December 31, 2023, with revenue of about HK$50.2 million, a year-on-year decrease of 44.1%; net loss attributable to the company's owners was about HK$22.2 million, a year-on-year decrease of about 71.5%; and a loss of 1.33 HK cents per share. The decline in revenue was mainly due to the further strengthening of the hierarchical classification management policies for the adoption of antimicrobials in many regions of mainland China, and the adverse effects continued. As a result, demand for the Group's main product, second-generation cephalosporin products (1.0g), declined this year.
Zhitong FinanceMar 25 10:07 ET
NEW RAY MEDIC: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Futu NewsMar 25 10:02 ET · Announcements
New Ray Medicine International Forecasts Decline in 2023 Loss
New Ray Medicine International Holding (HKG:6108) expects a net loss of up to HK$30 million for the year 2023, down from HK$77.9 million in 2022, a March 15 filing on the Hong Kong bourse by the pharm
MT NewswiresMar 18 07:03 ET
Xinrui Pharmaceuticals (06108.HK) expects a sharp reduction in annual losses
Gelonghui, March 15, 丨 Xinrui Pharmaceuticals (06108.HK) announced that the company expects to record a net loss of no more than HK$30.0 million for the year ended 31 December 2023, while in the previous year, the Group recorded a net loss of approximately HK$77.9 million. The sharp reduction in expected losses for fiscal year 2023 is mainly due to (i) no recording of equity settlement expenses on a share-based basis. The relevant expenses for FY2022 were approximately HK$10.4 million, as confirmed by the Group granting share options to directors and employees in FY2022, and the Group did not record any in FY2023
Gelonghui FinanceMar 15 09:23 ET
NEW RAY MEDIC: INSIDE INFORMATION - SUBSTANTIAL REDUCTION IN LOSS
Futu NewsMar 15 09:19 ET · Announcements
搞经济 抄底 加仓 :
it been around for 2yrs. Covid lockdown nothing new and will not impact anything now anymore.
The Up and Down all depends on the FED magical finger and his toy (Green / RED) Button
solo investOP 搞经济 抄底 加仓: Yess I definitely agree
SpyderCall : what about china which is easing monetary policy while the Fed is tightening. Do you think we should move money into chinese equities?? @Clouden 云 经济
No Data
No Data